



Bloom Burton & Co.
Healthcare Investor Conference
May 4 - 5, 2015



bloom burton & co

*/accelerating returns in healthcare**

We gratefully acknowledge the support of our sponsors

Welcome to the 2015 Bloom Burton & Co. Healthcare Investor Conference

Gold Sponsors:

Bloom Burton exists to accelerate returns in healthcare and there is no better illustration than this very conference, which brings together hundreds of entrepreneurs and investors to meet, learn and plan for growth.



This has been an extraordinary year for the Canadian healthcare sector. Financing for commercial healthcare companies has never been stronger and thanks to the leadership and success of Knight Therapeutics and Concordia Healthcare, in particular, there is broad investor interest from Canadian institutional funds and investment advisors. For the first time in many years capital is floating into the better development-stage biotechnology and medical technology companies such as Clementia Pharmaceuticals and ESSA Pharma, which have found venture and crossover capital from the most discerning U.S. and international sources.

Silver Sponsors:

In addition to our traditional investment banking work - equity research, capital raising and M&A and business advisory - we have dramatically expanded our asset management affiliate, delivering terrific returns for investors in our public equity and special situations lending funds. Bloom Burton is also quietly forming and incubating entirely new companies, and we are proud that one of our first ventures, Qing Bile Therapeutics, will be presenting this year.



We are so proud of our talented and dedicated team, who work with such dedication to serve our clients. We strive to produce exceptional deliverables and outcomes. We are here to support you today as you meet and plan for the success of the healthcare sector in Canada.

Have a wonderful day!

Brian and Jolyon

DAY 1 / MAY 4, 2015

TIME

DOMINION BALLROOM

8:30AM Welcome and Introductory Remarks

Moderator: JOLYON BURTON, Bloom Burton & Co.

8:40AM **Speaker:** ADAM FEUERSTEIN, TheStreet.com

Company Presentations

CITY HALL	CHURCHILL	MACKENZIE
-----------	-----------	-----------

9:30AM	Apotex	Aptose Biosciences	Antibe Therapeutics
10:00AM	Cipher Pharmaceuticals	SQL Diagnostics	Zymeworks
10:30AM	CRH Medical	Oncolytics Biotech	Parvus Therapeutics <i>Introductory remarks:</i> Don Iveson , Mayor of Edmonton
11:00AM	Novadaq Technologies	BELLUS Health	Milestone Pharmaceuticals
11:30AM	Knight Therapeutics	Hamilton Thorne	Newtopia

DOMINION BALLROOM

12:00PM Lunch
Venture Capital Panel Discussion

Moderator: BRIAN BLOOM, Bloom Burton & Co.
Panelists: JEREL DAVIS, Versant Ventures
OTELLO STAMPACCHIA, Omega Funds
PETER VAN DER VELDEN, Lumira Capital
SCOTT WEINER, Pappas Ventures
ASISH XAVIER, Johnson & Johnson Innovation

Company Presentations

1:30PM	Patient Home Monitoring	Theratechnologies	Induce Biologics
2:00PM	Tribute Pharmaceuticals	Telesta Therapeutics	Turnstone Biologics
2:30PM	Pharmascience	Centric Health	Qing Bile Therapeutics
3:00PM	Trimel Pharmaceuticals	Sophiris Bio	Profound Medical
3:30PM	Merus Labs	Avivagen	ChipCare

4:30PM Cocktail Reception
Dominion Ballroom, Sheraton

DAY 2 / MAY 5, 2015

TIME

DOMINION BALLROOM

8:30AM **Speaker:** AVIK S. A. ROY, Roy Healthcare Research

Company Presentations

CITY HALL	CHURCHILL	MACKENZIE
-----------	-----------	-----------

9:30AM	ProMetic Life Sciences	Biosyent Pharma	Colibri Technologies
10:00AM	Trillium Therapeutics	Pediapharm	Intelljoint Surgical
10:30AM	Æterna Zentaris	GeneNews	CannTrust
11:00AM	Aquinox Pharmaceuticals	Nuvo Research	Bedrocan Cannabis
11:30AM	Clementia Pharmaceuticals	Medicure	MariCann

DOMINION BALLROOM

12:00PM Lunch
Buyside Investor Panel Discussion

Moderator: BRIAN BLOOM, Bloom Burton & Co.
Panelists: FRANKLIN BERGER, FMB Research
DHESH GOVENDER, Tera Capital Corporation
EDEN RAHIM, Next Edge Capital
DAVID SABLE, Special Situations Fund
ERIC SHIOZAKI, Novo Ventures

Company Presentations

1:30PM	Xenon Pharmaceuticals	Convato Health International	Formation Biologics
2:00PM	ESSA Pharmaceuticals	LED Medical Diagnostics	Kairos Therapeutics
2:30PM	Aurinia Pharmaceuticals	Agility Health	Medicenna Therapeutics
3:00PM	Cardiome Pharma	Microbix Biosystems	Qu Biologics
3:30PM	Transition Therapeutics	Response Biomedical	viDA Therapeutics



Network: SHERATON_MEETINGS
Username: BLO291
Password: pudato

Corporate presentations will be available via a weblink to be emailed to attendees after the conference.

Æterna Zentaris

MAY 5, 2015 10:30AM
CITY HALL

TSX:AEZ, NASDAQ:AEZS

Æterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The Company's lead drug development program is a Phase 3 trial in endometrial cancer with zoptarelin doxorubicin. Its lead commercial program is the co-promotion of EstroGel, ASCEND Therapeutics' estrogen therapy product.

Agility Health

MAY 5, 2015 2:30PM
CHURCHILL

TSXV:AH1

Through its subsidiary and principal operating entity, Agility Health, LLC, Agility Health operates a multi-state network of outpatient rehabilitation clinics and provides contracted services to hospitals, nursing homes and other institutional clients, providing care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and a variety of other injuries and conditions. In addition, Agility Health provides a number of ancillary services related to physical rehabilitation, including practice management software systems and custom orthotics.

Antibe Therapeutics

MAY 4, 2015 9:30AM
MACKENZIE

TSXV:ATE

Antibe Therapeutics is a human drug development company with a portfolio of patented anti-inflammatory drug candidates targeting significant global markets. The company creates improved versions of existing anti-inflammatory drugs by linking an off-patent, 'base' drug to an Antibe-patented compound that releases hydrogen sulfide, resulting in a new drug with significantly improved properties compared with the base drug. Hydrogen sulfide has anti-inflammatory, anti-nociceptive (pain-killing) and vasodilatory properties. These improved drugs are covered by new 'composition of matter' patents.

Apotex

MAY 4, 2015 9:30AM
CITY HALL

PRIVATE

Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has approximately 5,500 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R&D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year - the largest amount of any pharmaceutical company in this country.

Aptose Biosciences

MAY 4, 2015 9:30AM
CHURCHILL

TSX: APS, NASDAQ: APTO

Aptose Biosciences is a science-driven biotechnology company advancing first-in-class therapeutics to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Aptose is developing personalized medicines for precision treatment of these diseases, based on a patient's specific gene signature. The company is also creating proprietary companion diagnostic tools to identify predisposed sensitivities to targeted therapies for use in single-agent or combination regimens. In the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies.

Aquinox Pharmaceuticals

MAY 5, 2015 11:00AM
CITY HALL

NASDAQ: AQXP

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and clinical trials with AQX-1125, Aquinox is now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

Aurinia Pharmaceuticals

MAY 5, 2015 2:30PM
CITY HALL

TSXV: AUP, NASDAQ: AUPH

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis ("LN"). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Avivagen

MAY 4, 2015 3:30PM
CHURCHILL

TSXV: VIV

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV" and on OTC Pink as "CHEXF." The Company's goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness. Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island.

Bedrocan Cannabis

MAY 5, 2015 11:00AM
MACKENZIE

TSX: BED

Bedrocan is focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains represent the world's only standardized (pharmaceutical grade), full-bud medicinal cannabis, and have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research, and has a commitment to quality with ISO 9001-rated production processes and product development, on an international scale.

BELLUS Health

MAY 4, 2015 11:00AM
CHURCHILL

TSX: BLU

BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIIACTA™ in Phase III for AA amyloidosis, KIIACTA™ for sarcoidosis, clinical stage Shigamab™ for sHUS and a research-stage project for AL amyloidosis. The lead program KIIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIIACTA™ is partnered with global private equity firm Auvén Therapeutics.

Biosyent Pharma

MAY 5, 2015 9:30AM
CHURCHILL

TSXV: RX

BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

CannTrust

MAY 5, 2015 10:30AM
MACKENZIE

PRIVATE

Federally licensed and regulated, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the Medical Cannabis industry and applies this expertise to produce quality pharmaceutical-grade Medical Cannabis for patients in need. CannTrust™ is committed to research and innovation, to contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis and to developing novel mechanisms that will make it easier for certain patients to take Medical Cannabis. The company supports ongoing patient education about Medical Cannabis, and has launched a compassionate use program to support patients with financial needs.

Cardiome Pharma

MAY 5, 2015 3:00PM
CITY HALL

TSX: COM, NASDAQ: CRME

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for the treatment of acute coronary syndrome patients.

Centric Health

MAY 4, 2015 2:30PM
CHURCHILL

TSX: CHH

Centric Health's vision is to be Canada's premier healthcare company, providing innovative solutions centered on patients and healthcare professionals. As a diversified healthcare company with investments in several niche service areas, Centric Health currently has operations in medical assessments, disability and rehabilitation management, physiotherapy and surgical centres, homecare, specialty pharmacy and wellness and prevention. With knowledge and experience of healthcare delivery in international markets and extensive and trusted relationships with payers, physicians, and government agencies, Centric Health is pursuing expansion opportunities into other healthcare sectors to create value for all stakeholders with an unwavering commitment to the highest quality of care.

ChipCare

MAY 4, 2015 3:30PM
MACKENZIE

PRIVATE

ChipCare is a social enterprise developing a handheld cell analyzer based on mobile technology. Its vision is to become a global leader in developing and providing point-of-care (POC) testing solutions for global health. ChipCare's mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. The envisioned product entails two components: handheld reader and disposable test slide. The revenue will mainly be generated from sales of disposable test slides (consumables). Our proprietary detection technique enables testing of multiple diseases from a single drop of blood sample, including cell counting, protein/enzyme and pathogen detection.

Cipher Pharmaceuticals

MAY 4, 2015 10:00AM
CITY HALL

TSX: CPH, NASDAQ: CPHR

Cipher Pharmaceuticals is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.

Clementia Pharmaceuticals

MAY 5, 2015 11:30AM
CITY HALL

PRIVATE

Clementia is a privately held, clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people living with rare diseases. The company is advancing a novel retinoic acid receptor gamma agonist to address diseases of heterotopic ossification, including fibrodysplasia ossificans progressiva.

Colibri Technologies

MAY 5, 2015 9:30AM
MACKENZIE

PRIVATE

Colibri Technologies is dedicated to developing technologies that will improve patient quality of life, reduce healthcare costs and enable better treatment options for large patient populations. Our goal is to make cardiac procedures safer, faster, cheaper and more effective through image guidance.

Convalo Health International

MAY 5, 2015 1:30PM
CHURCHILL

TSXV: CXV

Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In May 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. Since May, the business has operated under the brand name BLVD Centers (www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative.

CRH Medical

MAY 4, 2015 10:30AM
CITY HALL

TSX: CRH

CRH Medical Corporation is a North American company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves.

ESSA Pharma

MAY 5, 2014 2:00PM
CITY HALL

TSXV: EPI

ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA is developing drugs, which selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.

Formation Biologics

MAY 5, 2015 1:30PM
MACKENZIE

PRIVATE

Formation Biologics Inc. (formerly AvidBiologics) is an oncology drug development company dedicated to anti-cancer biologics. The company's lead compound, AVID100, is a novel antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR). EGFR is overexpressed by a numerous solid tumors including breast, lung, pancreatic, and others. In preclinical studies, AVID100 exhibited significant anti-tumour activity in xenograft models and was well-tolerated in primate safety studies. AVID100 is currently undergoing IND-enabling development with Phase I scheduled for 2016. In addition, Formation is developing a pipeline of anti-cancer biologics against a number of undisclosed targets.

GeneNews

MAY 5, 2015 10:30AM
CHURCHILL

TSX: GEN

GeneNews is a cancer diagnostics company focused on the development, licensing and commercialization of genomic-based clinical laboratory tests. Our innovative diagnostic tests and diagnostic tools provide valuable information to help doctors determine the appropriate treatment protocols based on an individual's risk profile. The company has adopted a 3-dimensional approach to help physicians improve patient outcomes. The three dimensions include: Early diagnosis of disease, Guiding treatment protocols, Remission and Recurrence monitoring.

Hamilton Thorne

MAY 4, 2015 11:30AM
CHURCHILL

TSX: HTL

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and developmental biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in fertility, regenerative medicine, and stem cell research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses.

Induce Biologics

MAY 4, 2015 1:30PM
MACKENZIE

PRIVATE

Induce Biologics Inc. is a regenerative medicine company based in Toronto, Canada, that is developing bioimplants for bone regeneration. The lead product candidate, URIST™, is a novel implant that contains bone morphogenetic protein (BMP), and a proprietary carrier; this carrier provides a gradual, multi-phasic delivery of BMP. This gradual delivery allows for the use of less BMP compared to current products, making it more cost-effective. Also, since all known BMP adverse events and toxicity issues have been related to higher doses of BMP, the ability to use lower doses provides a potential risk benefit as well.

Intellijoint Surgical

MAY 5, 2015 10:00AM
MACKENZIE

PRIVATE

Intellijoint HIP™ is a proprietary miniaturized system that is intended to help surgeons in the selection and positioning of orthopaedic implants during hip replacement surgery. Intellijoint HIP™ consists of 2 disposable sensors (1 sensor, 1 marker) and a display unit. With Intellijoint HIPTM, surgeons are able to increase the accuracy of hip replacement surgery. It's an instrument that assists them to make the critical measurements that studies in computer assisted surgery have shown to enhance clinical outcomes.

Kairos Therapeutics

MAY 5, 2015 2:00PM
MACKENZIE

PRIVATE

Kairos Therapeutics is developing a pipeline of antibody-drug conjugate (ADC) therapeutics for the treatment of various forms of cancer. The technology was developed in-house at The Centre for Drug Research and Development (CDRD) and has been exclusively licensed to Kairos from CDRD through its commercialization vehicle, CDRD Ventures Inc. Kairos is developing a family of ADCs based on a proprietary toxin and linker platform. Proprietary site-specific conjugation methodology has been developed to maintain target affinity, effector function, and increase circulation half-life.

Knight Therapeutics

MAY 4, 2015 11:30AM
CITY HALL

TSX: GUD

Knight Therapeutics Inc. is a publicly traded, specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight's products are sourced through partnerships.

LED Medical Diagnostics

MAY 5, 2015 2:00PM
CHURCHILL

TSXV: LMD

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiary LED Dental, provides dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

MariCann

MAY 5, 2015 11:30AM
MACKENZIE

PRIVATE

Established in 2013, MariCann has built a team of professionals with extensive experience in the pharmaceutical industry and sought out only the most influential names in the medical cannabis arena to ensure best production practices and quality assurance are delivered to produce marijuana for patients seeking a safer and more natural alternative to conventional medical treatments. So, while they are a relatively new company in Medical Cannabis their experienced team is anything but. Together, they collectively bring more than 150 years of pharmaceutical experience to patients, healthcare practitioners and government bodies, and are committed to building on that experience to push for acceptance and changes to the medicinal cannabis discussion.

Medicenna Therapeutics

MAY 5, 2015 2:30PM
MACKENZIE

PRIVATE

Medicenna Therapeutics, Inc ("Medicenna"), is a clinical stage, privately held, company led by a team of experienced entrepreneurial executives with an enviable track record. Focused on breakthrough cancer therapies, Medicenna is taking the lead in developing first-in-class Empowered Cytokines™ (ECs) as superior alternatives to Antibody Drug Conjugates (ADCs). These fusion proteins are designed to harness the exceptional specificity and affinity of Superkines™ (engineered cytokines) to selectively and simultaneously deliver pro-apoptotic agents to the bulk tumor, tumor microenvironment and cancer stem cells.

Medicure

MAY 5, 2015 11:30AM
CHURCHILL

TSXV: MPH

Medicure is a specialty pharmaceutical company focused on the development and commercialization of novel small molecule therapeutics. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.

Merus Labs

MAY 4, 2015 3:30PM
CITY HALL

TSX: MSL, NASDAQ: MSLI

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Microbix Biosystems

MAY 5, 2015 3:00PM
CHURCHILL

TSX: MBX

Microbix Biosystems specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company's pipeline of innovative technologies and products also includes LumiSort, a semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots; and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine.

Milestone Pharmaceuticals

MAY 4, 2015 11:00AM
MACKENZIE

PRIVATE

Milestone is a clinical stage drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product, MSP-2017, is a novel and potent short-acting calcium channel antagonist for the systemic treatment of PSVT that just completed Phase 1 studies. The Company has assembled a world-class drug development team and advisory board of key opinion leaders with significant cardiovascular expertise in cardiology, regulatory affairs, and drug development.

Newtopia

MAY 4, 2015 11:30AM
MACKENZIE

PRIVATE

Newtopia is a personalized health company leveraging genetic testing and the latest engagement science to inspire individuals to make healthy lifestyle decisions. Newtopia's patented enterprise health engagement platform combines personality-matched coaching with mobile social health communities and genetically tailored health products to keep clients motivated and on track. Newtopia is partnering with insurers, employers and brands to offer disease prevention and management programs to risk-assessed individuals that deliver proven sustainable outcomes, quantifiable cost savings and a substantive ROI.

Novadaq Technologies

MAY 4, 2015 11:00AM
CITY HALL

TSX: NDQ, NASDAQ: NVDQ

Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ's global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 130 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.

Nuvo Research

MAY 5, 2015 11:00AM
CHURCHILL

TSX: NRI

Nuvo is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group currently has four commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders.

Oncolytics Biotech

MAY 4, 2015 10:30AM
CHURCHILL

TSX: ONC, NASDAQ: ONCY

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus.

Parvus Therapeutics

MAY 4, 2015 10:30AM
MACKENZIE

PRIVATE

Introductory remarks:
Don Iveson, Mayor of Edmonton

Parvus is a privately held biopharmaceutical company developing and commercializing a nanotechnology-based therapeutic platform for the treatment of autoimmunity. We believe that our therapeutic candidates, Navacims, have the potential to radically improve the lives of patients with autoimmune disease. Navacims, are nanoparticles conjugated to immune system proteins that can be readily modified to target a range of autoimmune conditions like type I diabetes (T1D), multiple sclerosis and rheumatoid arthritis, amongst others. Our lead candidates reverse T1D and Multiple Sclerosis in animals.

Patient Home Monitoring

MAY 4, 2015 1:30PM
CITY HALL

PRIVATE

PHM is an acquisition-oriented, fast-growing and profitable company offering patients with heart disease and other chronic health conditions home-based services in the US. PHM is acquiring companies in a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM has identified and is evaluating profitable, annuity-based companies to acquire at favorable prices for their patient databases and technical expertise. PHM's post-acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The result to date has been growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.

Pediapharm

MAY 5, 2015 10:00AM
CHURCHILL

TSXV: PDP

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative portfolio of commercialized products includes NYDA®, a breakthrough treatment for head lice; Pediapharm Naproxen Suspension, the only prescription NSAID available in Canada; EpiCeram®, a non-steroid emulsion for eczema; KoolEffect® which reduces the symptoms of fever; and VapoLyptus®, a soothing vapour patch of Eucalyptus and Camphor.

Pharmascience

MAY 4, 2015 2:30PM
CITY HALL

PRIVATE

Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. We are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service. Our state-of-the-art R&D laboratory and production facilities are located in Montreal, Quebec. Our Canada-wide customer base includes pharmacists, drug wholesalers and major retailers. Investment in research and development at Pharmascience amounts to CAD\$30 million annually. In 2011, we invested CAD\$40 million to expand our facilities.

Profound Medical

MAY 4, 2015 3:00PM
MACKENZIE

PRIVATE

Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland. Profound's novel technology combines Magnetic Resonance Imaging (MRI) technology with ultrasound thermal energy that is delivered via a trans-urethral approach. This method of prostate cancer therapy provides highly accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials.

ProMetic Life Sciences

MAY 5, 2015 9:30AM
CITY HALL

TSX: PLI

ProMetic Life Sciences Inc. is an established biopharmaceutical company with widely recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its innovative technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation.

Qing Bile Therapeutics

MAY 4, 2015 2:30PM
MACKENZIE

PRIVATE

Qing Bile Therapeutics Inc., is a Vancouver-based biotech developing novel treatments for severe orphan liver diseases. Qing's THBA bile acid platform is built upon findings from research on transport defects in genetic liver diseases by the Victor Ling laboratory at the BC Cancer Agency. Compared to other bile acid-based drugs, Qing's product candidates have properties that preclinical studies suggest may translate into improved efficacy and safety, as well as being complementary to other bile-modulating approaches such as Intercept's obeticholic acid. Qing's strategy is to initiate clinical development in targeted orphan populations, whose molecular pathogenesis provides a direct mechanistic rationale for therapeutic benefits from its drug candidates, while also exploring larger market liver disease opportunities.

Qu Biologics

MAY 5, 2015 3:00PM
MACKENZIE

PRIVATE

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases. The company is currently recruiting participants for a clinical trial in Crohn's disease and a Phase 2a open-label clinical trial in recurrent non-small cell lung cancer to study SSI treatment. A clinical trial in ulcerative colitis has received Health Canada approval and will begin in Q2 2015.

Response Biomedical

MAY 5, 2015 3:30PM
CHURCHILL

TSX: RBM

Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP® platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications.

Sophiris Bio

MAY 4, 2015 3:00PM
CHURCHILL

NASDAQ: SPHS

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris plans to initiate a Phase 2 proof of concept study of PRX302 for the treatment of localized low to intermediate risk prostate cancer prior to the end of the first half of 2015.

SQI Diagnostics

MAY 4, 2015 10:00AM
CHURCHILL

TSX: SQD

SQI Diagnostics is a diagnostics company that develops the most advanced multiplexed tests and automated systems for customers who need to measure a wide variety of biomarkers in blood or other common sample types. Multiplexed tests detect multiple analytes from a single biological specimen, and at SQI, it's done in an automated fashion. SQI technology supports better healthcare through faster and more accurate multiplexing technology. We have 12 patents and all of the know-how to simplify your multiplex testing needs. Our multiplexed tests and automated systems greatly simplify work flow. With full service product commercialization, hands-free processing, automated data analysis and reporting, SQI delivers the results you needed yesterday, quickly and efficiently.

Telesta Therapeutics

MAY 4, 2015 2:00PM
CHURCHILL

TSX: TST

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta is targeting the filing of a Biologics Licensing Application (BLA) with the U.S. FDA in 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.

Thera-technologies

MAY 4, 2015 1:30PM
CHURCHILL

TSX: TH

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and an improved quality of life. Our lead product, EGRIFTA® (tesamorelin for injection), was approved by the U.S. Food and Drug Administration in November 2010 and is the only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

Transition Therapeutics

MAY 5, 2015 3:30PM
CITY HALL

TSX: TTH, NASDAQ: TTHI

Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS and metabolic disease indications. The Company's wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer's disease and Down syndrome. Transition's lead metabolic drug candidate is TT401 (LY2944876) for the treatment of type 2 diabetes and accompanying obesity.

Tribute Pharmaceuticals

MAY 4, 2015 2:00PM
CITY HALL

TSXV: TRX

Tribute Pharmaceuticals Canada Inc. ("Tribute") is a leading Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US. The Company targets several therapeutic areas but has a particular interest in products for the treatment of pain, neurology, dermatology, cardiology, endocrinology and specialty care. Tribute also sells Uracyst® and NeoVisc® internationally through a number of strategic partnerships. Tribute currently markets NeoVisc® Single Dose, NeoVisc® Triple Dose, Uracyst®, Soriatane®, Bezalip® SR, Cambia®, Fiorinal®, Fiorinal® C, Visken® and Viskazide in Canada and has the US rights to Bezalip® SR and global rights to Uracyst® and NeoVisc®. Additionally, Tribute has the exclusive Canadian rights to bilastine in Canada (not yet approved).

Trillium Therapeutics

MAY 5, 2015 10:00AM
CITY HALL

TSX: TR, NASDAQ: TRIL

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. Our lead program SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system.

Trimel Pharmaceuticals

MAY 4, 2015 3:00PM
CITY HALL

TSX: TRL

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system ("TriVair™"). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism ("low testosterone" or "Low-T") and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada.

Turnstone Biologics

MAY 4, 2015 2:00PM
MACKENZIE

PRIVATE

Turnstone Biologics extends the boundaries of the emerging field of cancer immunotherapy. Turnstone's technology, Marabex, is a first-in-class tumor targeted oncolytic vaccine. Building on the recent clinical validation of oncolytic viruses, Marabex combines potent tumor killing effects with the benefits of a cancer vaccine. Turnstone's lead OV, Maraba is exquisitely tumor selective and alone, prolongs survival in a variety of tumor models in animals. Maraba also acts as a vaccine through a Tumour Associated Antigen (TAA) transgene that is expressed by the OV in tumour cells and immune cells, with the lead product employing the clinically validated MAGE-A3 antigen. Enhanced immune responses are achieved by utilizing a heterologous prime-boost vaccine strategy with an initial priming viral vector (Adenovirus-MAGE-A3). Marabex induces T-cell activation to much higher levels than previously reported for clinically active vaccines.

viDA Therapeutics

MAY 5, 2015 3:30PM
MACKENZIE

PRIVATE

viDA Therapeutics is a research based biotechnology company using its expertise, based on newly identified pathological roles for a family of granule secreted enzymes called Granzymes, to discover and develop novel, first-in-class drugs for the treatment of inflammatory and age related conditions of the skin, respiratory, musculoskeletal, cardiovascular, and neurological systems.

Xenon Pharmaceuticals

MAY 5, 2015 1:30PM
CITY HALL

NASDAQ: XENE

Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech.

Zymeworks

MAY 4, 2015 10:00AM
MACKENZIE

PRIVATE

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company's novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Bloom Burton exists to Accelerate Returns in Healthcare

The goal of all investors, companies and organizations is to achieve a monetizing event, such as the ability to raise capital, perform meaningful research and development, license or commercialize products, reach profitability or execute a strategic transaction.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade and, as a result of our deep expertise and experience, our clients achieve a faster path to their monetizing events.

Bloom Burton works with institutional and individual investors looking to invest in the healthcare sector. We also work with healthcare companies and organizations of all sizes and stages of development, who seek advice and capital.

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international healthcare-specialized investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Our Services

Our services help identify, cultivate and create investment opportunities in the healthcare sector, on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients:

- Raising capital and financing
- Mergers and acquisition advisory
- Equity Research
- Monetization Planning (both strategic and scientific consulting)
- Direct Investments through the Bloom Burton Funds
- Company Creation and Incubation

Let us know how we can help you accelerate your returns in the healthcare sector.

Raising capital and financing

From steering seed money to promising new life science ventures to facilitating private financing or raising public capital, Bloom Burton & Co. connects investors with attractive healthcare businesses poised for growth and profit.

As investment bankers, we nurture relationships between worthy companies and engaged investors who want to provide funding and participate in the growth of the healthcare sector.

Raise funding through a range of securities

We deal in the full range of securities to suit the capital requirements, or risk and return objectives, of companies and investors, from equity and debt issues to private placements or participating in selling groups of public offerings.

Garner attention of top fund managers

Our firm's unique professional relationships with international healthcare-specialized private and public fund managers has helped attract capital from around the world to Bloom Burton's issuer clients.

<p>Public Offering USD \$5,200,000</p>  <p>TRILLIUM THERAPEUTICS INC</p> <p>Common and Preferred Shares April 2015 Financial Advisor</p>	<p>Private Placement \$5,500,000</p>  <p>Pediapharm</p> <p>Convertible Debentures March 2015 Agent</p>	<p>Bought Deal \$27,370,000</p>  <p>CRH Medical CORPORATION</p> <p>Common Shares March 2015 Underwriter</p>
--	---	--

<p>Private Placement USD \$12,000,000</p>  <p>ESSA</p> <p>Special Warrants January 2015 Agent</p>	<p>Bought Deal \$100,000,000</p>  <p>knight</p> <p>Common Shares December 2014 Underwriter</p>	<p>Public Offering \$30,026,500</p>  <p>TRIBUTE PHARMACEUTICALS</p> <p>Units July 2014 Selling Group</p>
---	---	---

Mergers and acquisition advisory

The mergers and acquisitions advisory capability at Bloom Burton guides clients to conceptualize, structure and execute transactions to maximize returns and company performance.

Our team's professional expertise in healthcare and intellectual property also allows us to guide our clients with scientific and technical due diligence on their M&A opportunities and development strategies.

Guiding a broad range of M&A-type transactions:

- Strategic Acquisitions
- Sales & Divestitures
- Spinoffs & Splitoffs
- Strategic Partnerships
- Reorganization & Restructuring
- Leveraged Buyouts
- Takeover Defenses and Proxy Contests
- Special Committee Assignments
- Fairness/Valuation Opinions

<p>M&A Transaction USD \$73,000,000</p>  <p>CRH Medical CORPORATION</p> <p>Completes acquisition of Gastroenterology Anesthesia Associates, LLC</p> <p>December 2014 Financial Advisor to CRH</p>	<p>Asset Sale USD \$45,000,000</p>  <p>HORIZON</p> <p>Acquires Pennsaid® 2% US</p>  <p>NUVO</p> <p>October 2014 Exclusive Financial Advisor to Nuvo</p>	<p>M&A Transaction Not disclosed</p>  <p>paladin</p> <p>Completes acquisition of TRITON PHARMA INC.</p> <p>Advisor to Triton Pharma January 2014</p>
<p>M&A Transaction Approx. \$357,000,000</p>  <p>Mitsubishi Tanabe Pharma acquires majority stake in medicago</p> <p>September 2013 Advisor to Medicago Management</p>	<p>M&A Transaction Approx. \$13,000,000</p>  <p>Bellus HEALTH</p> <p>completes acquisition of Thallion PHARMA</p> <p>August 2013 Advisor to Thallion</p>	<p>M&A Transaction Approx. \$510,000,000</p>  <p>GILEAD</p> <p>completes acquisition of YM BIOSCIENCES INC.</p> <p>December 2012 Advisor to YM BioSciences</p>

Equity research in Canada's healthcare sector

Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

Charting what's new in biotech: Our Canadian Healthcare Roadmap Publication

Our Canadian Healthcare Roadmap report, published twice a year, is essential reading for institutional investors to track drugs and medical products in development or being commercialized by public healthcare companies, as well as milestones that could impact share performance.

Distribution to healthcare research

Request to be added to Bloom Burton's equity research distribution list. Email Brian Bloom at bbloom@bloomburton.com.

Research Coverage



Monetization planning

Understanding the business opportunities to bring healthcare advances to market, and how to successfully exploit them, are key to any company's commercial and financial success. It is also key to investor returns.

Our management consulting practice provides capital market advice, plus scientific, clinical and medical insight to help innovative companies position themselves to profit from their good ideas and achieve a monetizing event. We structure our work as either defined projects or long-term arrangements.

We speak with large companies and investors every day, and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, and consider new therapeutic indications and clinical designs, catalogue and diligence new products or companies for acquisition.



Direct investment: Bloom Burton Funds

Through our affiliate asset management firm, Bloom Burton Investment Group, we sub-advise the following two fund products administered by Stratigis Capital Advisors Inc., which offer investors the opportunity to invest in a diversified portfolio of healthcare companies.

Bloom Burton Canadian Healthcare Fund LP

The Bloom Burton Canadian Healthcare Fund exists to achieve superior returns by investing primarily in equity and equity-linked securities of publicly traded Canadian healthcare and biotechnology companies. The Fund invests in companies of all capitalization sizes with a focus on the biotechnology, emerging pharmaceutical, medical device, diagnostic and healthcare service industries. The manager employs fundamental, bottom-up quantitative analysis and a qualitative research methodology to identify mispriced securities or assets in a market in which Bloom Burton has unique insights, respected experience and long-standing relationships.

Fund Performance for the Bloom Burton Canadian Healthcare Fund LP:

2013:	23.2%
2014:	42.9%
2015 YTD:	34.2%
Since Inception:	136.8%

Bloom Burton Healthcare Structured Lending Fund I and II LP

The Bloom Burton Healthcare Structured Lending Funds I and II exist to achieve superior returns for investors providing debt or debt-like capital to emerging commercial-stage Canadian healthcare companies with assets and cash-flow to support debt, but seeking funding amounts not provided by traditional lenders. The Fund invests in both privately held and publicly traded companies using a variety of structures.

Fund Performance for the Bloom Burton Healthcare Structured Lending Fund LP:

2014:	33.2%
2015 YTD:	31.9%
Since Inception:	75.7%

Company creation and incubation

In very special situations, instead of providing services for cash fees, Bloom Burton partners with entrepreneurs and researchers to form and incubate new companies, in exchange for a founding equity position.

Bloom Burton leverages all of its services and skills:

- Advise on the company's corporate and capital structure;
- Catalog and select the best target indications based on commercial, competitive and scientific considerations;
- Design the optimal international patent strategy;
- Design preclinical and clinical programs to produce valuable evidence for financing and partnering;
- Support the optimal regulatory strategy;
- Advise on the identification, license or acquisition of complimentary intellectual property and assets;
- Recruit the best management team and Board to help execute the Company's strategy;
- Create marketing materials to inform, engage and transact with investors and partners;
- Raise seed and subsequent private and public capital; and
- Leverage the entire Bloom Burton platform to increase the exposure of the Company.

Company Creation  Qing Bile	Company Creation  Grey Wolf <small>Animal Health</small>	Company Creation  Albedo Biosciences Corp.
Company Creation  Appili Pharmaceuticals	Company Creation  Influorex Pharmaceuticals	Company Creation  Triumvira Immunogics

Unrivaled understanding of healthcare

Our team of expert professionals know how to create, grow and finance healthcare companies. Individually and together, our in-depth knowledge of healthcare can help bring you the guidance you need and accelerate the returns you seek.

Board of Directors

Morley Salmon
Chairman
msalmon@bloomburton.com

Brian Bloom
President
bbloom@bloomburton.com

Jolyon Burton
CEO
jburton@bloomburton.com

Investment Banking - Transactional Staff

Jolyon Burton
Head of Investment Banking
jburton@bloomburton.com

Michael Pollard
Vice President, Investment Banking
mpollard@bloomburton.com

James Rowland
Associate, Investment Banking
jrowland@bloomburton.com

Investment Banking - Scientific Staff

Armand Balboni
Partner and Managing Director of
Investment Banking
abalboni@bloomburton.com

John Holyoake
Associate
jholyoake@bloomburton.com

Evelyn Pau
Associate
epau@bloomburton.com

Antonia Borovina
Analyst
aborovina@bloomburton.com

Claudia Hui
Analyst
chui@bloomburton.com

Vincent Nadeau
Analyst
vnadeau@bloomburton.com

Equity Research

David Martin
Managing Director and Head of Equity Research
dmartin@bloomburton.com

Institutional Sales

Brian Bloom
Head of Institutional Sales
bbloom@bloomburton.com

Andrew Duckman
Vice President, Institutional Sales
aduckman@bloomburton.com

Corporate Staff


Ann McIntosh
Chief Compliance Officer
amcintosh@bloomburton.com

Stephanie Mazzone
Controller
smazzone@bloomburton.com

Erika Agnew
Senior Administrator
eagnew@bloomburton.com

Antonio LaRosa
Technology and Communications
Analyst
alarosa@bloomburton.com

Sheraton Centre Toronto Hotel 2nd Floor





bloom burton & co

*/accelerating returns in healthcare**

